EAM
ALXO icon

Eventide Asset Management’s ALX Oncology ALXO Stock Holding History

Eventide Asset Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-664,829
Closed -$3.01M – 141
2023
Q1 		$3.01M Sell
664,829
-237,171
-26% -$1.8M 0.06% 132
2022
Q4 		$10.2M Hold
902,000
– – 0.2% 105
2022
Q3 		$8.63M Buy
+902,000
New +$10.5M 0.17% 108
2021
Q3 		– Sell
-439,950
Closed -$24.1M – 153
2021
Q2 		$24.1M Buy
439,950
+349,950
+389% +$20.9M 0.32% 81
2021
Q1 		$6.64M Buy
+90,000
New +$7.08M 0.1% 123

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Eventide Asset Management's ALXO Position: Q2 2023 in Review

Eventide Asset Management sold out of ALX Oncology (ALXO) in Q2 2023, closing a stake of 664,829 shares — an estimated $3.01M sold.

Eventide Asset Management first reported a position in ALXO in Q1 2021 and held it in 5 quarters. The position peaked at $24.1M in Q2 2021. 75 funds tracked by Wall St. Rank hold ALXO as of Q2 2023.

  • Eventide Asset Management reported no remaining ALX Oncology position as of Q2 2023 after selling out during the quarter.
  • Eventide Asset Management sold 664,829 ALX Oncology shares in Q2 2023, an estimated $3.01M.
  • Eventide Asset Management first reported a position in ALX Oncology in Q1 2021 and held it in 5 quarters.
  • Eventide Asset Management's ALX Oncology position peaked at $24.1M in Q2 2021.
  • 75 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2023.

Based on Eventide Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.